Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q96P11
UPID:
NSUN5_HUMAN
Alternative names:
NOL1-related protein; NOL1/NOP2/Sun domain family member 5; Williams-Beuren syndrome chromosomal region 20A protein
Alternative UPACC:
Q96P11; B3KX04; B4DP79; G3V0G9; Q6ZUI8; Q96HT9; Q9NW70
Background:
The 28S rRNA (cytosine-C(5))-methyltransferase, also known as NOL1-related protein, NOL1/NOP2/Sun domain family member 5, and Williams-Beuren syndrome chromosomal region 20A protein, plays a crucial role in cellular function. It is an S-adenosyl-L-methionine-dependent methyltransferase that specifically methylates the C(5) position of cytosine 3782 in 28S rRNA. This methylation is essential for promoting protein translation, enhancing ribosome biogenesis and fidelity, without affecting them negatively.
Therapeutic significance:
Understanding the role of 28S rRNA (cytosine-C(5))-methyltransferase could open doors to potential therapeutic strategies.